The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12625000889459p
Ethics application status
Submitted, not yet approved
Date submitted
15/07/2025
Date registered
15/08/2025
Date last updated
15/08/2025
Date data sharing statement initially provided
15/08/2025
Type of registration
Prospectively registered

Titles & IDs
Public title
Duplex Ultrasound Surveillance After Endovascular Therapy for Peripheral Arterial Disease - Randomized Controlled Trial (SURVEIL)
Scientific title
The Efficacy of Duplex Ultrasound Surveillance after Endovascular Therapy for Preventing Complications of Peripheral Arterial Disease - Randomized Controlled Trial (SURVEIL)
Secondary ID [1] 314911 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Peripheral Arterial Disease 338227 0
Condition category
Condition code
Cardiovascular 334504 334504 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Duplex Ultrasound Surveillance (Intervention):
Participants will receive systematic clinical surveillance (comprehensive history, physical examination, and ankle-brachial pressure index measurement) by a vascular surgeon in the outpatient setting with adjunctive duplex ultrasound scanning performed by a sonographer. Imaging results will be available to treating clinicians at the time of consultation to inform clinical decision-making. Each surveillance review (including clinical review, ABI and duplex ultrasound scan) will take up to 90 minutes. Session attendance and completion will be recorded on routine case report form. This assessment is currently considered within the accepted standard of care.
To be performed at 3, 6, 9, 12, 18 and 24 months post-index-intervention.
Intervention code [1] 331516 0
Early detection / Screening
Comparator / control treatment
Clinical Surveillance Group (Comparator):
Participants will receive systematic clinical surveillance (comprehensive history, physical examination, and ankle-brachial pressure index measurement) by a vascular surgeon in the outpatient setting without routine duplex ultrasound scanning. Additional investigations may be ordered at clinical discretion based on symptom development, clinical deterioration, or significant changes in ankle-brachial pressure indices. Each surveillance review (including clinical and ABI) will take up to 45 minutes. Session attendance and completion will be recorded on routine case report form. This assessment is currently considered within the accepted standard of care.
To be performed at 3, 6, 9, 12, 18 and 24 months post-index-intervention.
Control group
Active

Outcomes
Primary outcome [1] 342189 0
Composite outcome of peripheral arterial disease complications including any of the following: 1) Target Vessel Occlusion 2) Major Adverse Limb Event (above-ankle amputation, new bypass, interposition graft revision, open thrombectomy or thrombolysis) 3) Death
Timepoint [1] 342189 0
Baseline (4-6 weeks post index procedure), 3-, 6-, 9-, 12-, 18- and 24-months post index-procedure. The primary endpoint is a time-to-event outcome assessed continuously over 24 months. The primary endpoint is a time-to-event outcome assessed continuously over 24 months.
Secondary outcome [1] 449859 0
Target Lesion Revascularization
Timepoint [1] 449859 0
3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [2] 449860 0
Clinically Driven Target Lesion Revascularization (CD-TLR)
Timepoint [2] 449860 0
3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [3] 449861 0
Minor Reinterventions on the Index Femoropopliteal Segment
Timepoint [3] 449861 0
3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [4] 449862 0
Minor Reinterventions on the Index Limb, not on the Femoropopliteal Segment
Timepoint [4] 449862 0
3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [5] 449863 0
Major Adverse Cardiac Event (MACE)
Timepoint [5] 449863 0
3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [6] 449864 0
Restenosis
Timepoint [6] 449864 0
3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [7] 449865 0
Target Vessel Primary Patency
Timepoint [7] 449865 0
Baseline (4-6 weeks post index procedure) and 24-months post index procedure.
Secondary outcome [8] 449866 0
Symptomatic Status
Timepoint [8] 449866 0
Baseline (4-6 weeks post index procedure), 3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [9] 449867 0
Index Wound Healing
Timepoint [9] 449867 0
3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [10] 449868 0
Generic Quality of Life
Timepoint [10] 449868 0
Baseline (4-6 weeks post index procedure) and 3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [11] 449869 0
Cost of Intervention
Timepoint [11] 449869 0
Baseline (4-6 weeks post index procedure), 6-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [12] 449870 0
Total No. of Duplexes
Timepoint [12] 449870 0
24-months post index procedure.
Secondary outcome [13] 449871 0
Cost-effectiveness outcomes
Timepoint [13] 449871 0
24-months post index procedure.
Secondary outcome [14] 450189 0
Target Vessel Primary-Assisted Patency
Timepoint [14] 450189 0
at 24-months post index procedure
Secondary outcome [15] 450190 0
Target Vessel Secondary Patency
Timepoint [15] 450190 0
at 24-months post index procedure
Secondary outcome [16] 450191 0
Disease-specific Quality of Life
Timepoint [16] 450191 0
Baseline (4-6 weeks post index procedure) and 3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.
Secondary outcome [17] 450715 0
Quality of life - Generic (SF-12)
Timepoint [17] 450715 0
Baseline (4-6 weeks post index procedure) and 3-, 6-, 9-, 12-, 18- and 24-months post index-procedure.

Eligibility
Key inclusion criteria
1. Must be over 18 years of age
2. Must have undergone endovascular intervention of the superficial femoral artery and/or ipsilateral popliteal artery for symptomatic peripheral arterial disease.
3. Target vessel must be patent at 4-6 weeks after operation, to exclude cases with acute technical failure from the trial. Patency defined as absence of a >75% stenosis on duplex at 4-6 weeks.
4. Must have adequate femoropopliteal inflow, defined as a triphasic waveform in the common femoral artery at time of enrolment.
5. Must have adequate tibial outflow, defined by at least a single patent tibial vessel to the ankle at time of enrolment
6. Must be able to give informed consent
7. Must have a life expectancy of at least 6 months
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participants participating in another clinical study
2. Participants that are not compliant with routine follow-up
3. Participants with previous above ankle amputation of the index limb
4. Participants with disease or other factor that would otherwise necessitate surveillance and prevent equipoise in the delivery of postoperative clinical vs duplex ultrasound surveillance

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation using a randomisation table created by computer software. Stratified by site and presenting symptom (claudication vs chronic limb-threatening ischaemia)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,WA,VIC
Recruitment outside Australia
Country [1] 27232 0
New Zealand
State/province [1] 27232 0

Funding & Sponsors
Funding source category [1] 319476 0
Hospital
Name [1] 319476 0
Prince of Wales Vascular Institute
Country [1] 319476 0
Australia
Primary sponsor type
Government body
Name
South Eastern Sydney Local Health District
Address
Country
Australia
Secondary sponsor category [1] 321965 0
None
Name [1] 321965 0
none
Address [1] 321965 0
Country [1] 321965 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 318046 0
South Eastern Sydney Local Health District HREC
Ethics committee address [1] 318046 0
Ethics committee country [1] 318046 0
Australia
Date submitted for ethics approval [1] 318046 0
22/05/2025
Approval date [1] 318046 0
Ethics approval number [1] 318046 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 142950 0
Dr Thomas Warburton
Address 142950 0
Suite 8, Level 7, Prince of Wales Private Hospital, Barker Street, Randwick, NSW, 2031
Country 142950 0
Australia
Phone 142950 0
+61 421872464
Fax 142950 0
Email 142950 0
Contact person for public queries
Name 142951 0
Thomas Warburton
Address 142951 0
Suite 8, Level 7, Prince of Wales Private Hospital, Barker Street, Randwick, NSW, 2031
Country 142951 0
Australia
Phone 142951 0
+61 421872464
Fax 142951 0
Email 142951 0
Contact person for scientific queries
Name 142952 0
Thomas Warburton
Address 142952 0
Suite 8, Level 7, Prince of Wales Private Hospital, Barker Street, Randwick, NSW, 2031
Country 142952 0
Australia
Phone 142952 0
+61 421872464
Fax 142952 0
Email 142952 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
Researchers
Conditions for requesting access:
Yes, conditions apply:
Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
All de-identified individual participant data
What types of analyses could be done with individual participant data?
Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.